骨髓增生异常综合征骨髓细胞免疫表型的探讨  

Study on Bone Marrow Immunophenotype in Myelodysplastic Syndrome

作　　者：胡喜梅[1] 薛文韬[2] 高晖[2] 陈珊珊[2] 

机构地区：[1]包头医学院第一附属医院血液科,014010 [2]北京医科大学人民医院血液病研究所,100083

出　　处：《临床血液学杂志》1998年第3期101-104,共4页Journal of Clinical Hematology

摘　　要：用流式细胞术分析45例原发性骨髓增生异常综合征（MDS）患者和10例良性血液病病人的骨髓细胞免疫表型。结果：88．9％MDS表现二系或二系以上免疫标志异常，基中CD2、CD71、CD13、CD33、HLA－DR、CD34免疫标志变化最大，明显高于对照组（P＜0．01）。RA组：CD2、CD71（P＜0．05）、HLA－DR（P＜0．01）明显高于对照组；RAEB：除上述标志同RA外，髓系相关标志CD13、CD33（P＜0．01）和干／祖细胞标志CD34明显增高（P＜0．05）；RAEB－t组：髓系相关标志CD13（P＜0．05）、CD33（P＜0．01）和干／祖细胞标志CD34、HLA-DR（P＜0．01）表达率增高。CD15：HLADR与CD15：CD34比值在RAEB－t最低。Bone marrow cells from 45 patients with newly diagnosed myelodysplastic syndrome (MDS)and 10 cases of non-malignant hematological diseases were evaluated by flow cytometric-immunophenotyping (FCM-IM). The panel of monoclonal antibody (MoAb ) used in this study included CD2, CD7, CD9, CD10, CD19, HLA-DR,CD13, CD14, CD15, CD33, CD,34, CD38, CD41, CD71, HIR (glycoprotein A ). 88. 9 % MDS patients showed 2 or more than 2 lineage cell surface markers abnormality. Compared to the control group, the positivity of CD2, CD71 and HLA-DR in refractory anemia (RA) were increased. While cells with myeloid surface markers had no statistical difference. On the other hand,in refractory anemia with excess blasts (RAEB) and transformation of RAEB groups,the positivity of early myeloid markers (CD13, CD33) and stem/progenitors (HLA-DR,CD34)were significantly higher than control group. The ratio of CD15:HLA-DR and CD15:CD34in RA were 1. 37 and 3. 73 respectively; in RAEB were 0. 94 and 3. 10; in RAEB-t were the lowest, i. e. 0. 82 and 2.03. FCM-IM might be useful tool for diagnosis and prediction in MDS.

关 键 词：骨髓增生异常 综合征 细胞免疫标志 诊断 

分 类 号：R551.304[医药卫生—血液循环系统疾病]